Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Colorectal Neoplasms 8Breast Neoplasms 8Neoplasm Metastasis 7Lung Neoplasms 6Rectal Neoplasms 5Sarcoma 4Prostatic Neoplasms 4Melanoma 4Colonic Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thymoma 2Neoplasms 2Mouth Neoplasms 2Head and Neck Neoplasms 2Carcinoma 2Adenomatous Polyposis Coli 2Uterine Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paranasal Sinus Neoplasms 1Papilloma 1Pain 1

Interventions

blinatumomab 3Cytarabine 2Cyclophosphamide 2Azacitidine 2venetoclax 1sabatolimab 1ruxolitinib 1pulrodemstat besilate 1pembrolizumab 1peginterferon alfa-2a 1nilotinib 1fludarabine 1daratumumab 1Zoledronic Acid 1Vitamin D 1Methotrexate 1Imatinib Mesylate 1GNKG168 1Dasatinib 1Clofarabine 1Celecoxib 1Calcium 1CD3 Complex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm, Residual × Celecoxib × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡